Latest News

Friday, May 26, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

NEJM Publishes Phase 3 Data for Epidiolex in Dravet Syndrome as Manufacturer Eyes Mid-2017 NDA Submission

The New England Journal of Medicine has published results from a Phase 3 study showing that Epidiolex (cannabidiol, GW Pharmaceuticals) reduces monthly convulsive seizure frequency compared to placebo…

Read the full story

Tuesday, May 23, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications

Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial

New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significant…

Read the full story

Friday, May 19, 2017 | Pain & Headache, Research and Publications

Migraine Prevalence Higher in Collegiate Athletes, New Study Finds

New findings suggest that collegiate athletes have an increased prevalence of migraines, with female athletes being particularly affected. In a retrospective cross-section survey, researchers evaluate…

Read the full story

Tuesday, May 16, 2017 | Product Launches and Updates, Research and Publications, Stroke & Cerebrovascular

Endovascular Intervention Found Effective for "Late Window" Stroke Patients: DAWN Trial Analysis

The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DA…

Read the full story

Tuesday, May 16, 2017 |

Endovascular Intervention Found Effective for “Late Window” Stroke Patients: DAWN Trial Analysis

The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DA…

Read the full story

Friday, May 12, 2017 | Research and Publications, Stroke & Cerebrovascular

Elevated B2M Levels Tied to Ischemic Stroke Risk in Women

β2-microglobulin (B2M) levels may be an indicator of ischemic stroke risk in women, according to new findings published in Neurology (May 10). Investigators performed a nested case-control study …

Read the full story

Friday, May 12, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results

New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In the EVOLVE-1 study, pati…

Read the full story

Monday, May 08, 2017 | General Medicine, Healthcare and Regulation, Healthcare Trends

Special Report—Expanding the Scope of Neurology: An Interview with Ralph L. Sacco, MD

Following are exerpts from Practical Neurology® magazine's interview with AAN President Ralph L. Sacco, MD. See the upcoming May edition for the full interview. When Ralph L. Sacco, MD…

Read the full story

Friday, May 05, 2017 | FDA Approval/Clearance, Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications

FDA Greenlights First New Treatment for ALS in More than Two Decades

The FDA has approved Radicava (edaravone, MT Pharma), as an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS). Radicava is the first treatment approved for the treatment of A…

Read the full story

Thursday, May 04, 2017 | Neuromuscular & Immune Disorders, Product Launches and Updates, Research and Publications

MS Topography App Launches

A new app that offers a new, visual way of understanding multiple sclerosis (MS) was recently launched at the American Academy of Neurology Annual Meeting in Boston. The app is a disease simulation th…

Read the full story

Wednesday, May 03, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Product Launches and Updates, Research and Publications

New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures

Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of NeuroPace’s RNS Syste…

Read the full story

Monday, May 01, 2017 |

Ralph Sacco Begins Two-Year Term as AAN President

Ralph L. Sacco, MD has assumed the role president of the American Academy of Neurology (AAN). Dr. Sacco is Professor and Chair of the Neurology department at the Miller School of Medicine at the Unive…

Read the full story

Friday, April 28, 2017 | Healthcare Trends, Research and Publications, Stroke & Cerebrovascular

AAN 2017 Meeting: Racial and Regional Disparities Identified in Endovascular Care Delivery

Access to endovascular care is significantly impacted by factors such as race, region, and hospital, according to findings presented this week at the American Academy of Neurology (AAN) Annual Meeting…

Read the full story

Wednesday, April 26, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

AAN 2017 Meeting: New Data Reinforce Efficacy of Ocrelizumab

New data presented at the American Academy of Neurology (AAN) Annual Meeting in Boston show the benefits of ocrelizumab in relapsing multiple sclerosis (MS). In a pooled analysis of Phase 3 …

Read the full story

Wednesday, April 26, 2017 | Movement Disorders, Research and Publications

AAN 2017 Meeting: New Evidence Suggest Parkinson’s Originates in the Gut

Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of…

Read the full story
Load More